Johnson & Johnson Reveals Game-Changing Bladder Cancer Data at AUA
April 21, 2025
Compelling first results from Cohort 4 of Phase 2b SunRISe-1 study show potential of TAR-200 monotherapy in patients with papillary-only, high-risk non-muscle invasive bladder cancer Johnson &